专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明公开

EP3262410A1 ASSAY TO DIAGNOSE AND TREAT DISORDERS OF THE ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION 有权
标题翻译：试验诊断和治疗障碍的补充激活的替代途径
公开(公告)号：EP3262410A1
公开(公告)日：2018-01-03
申请号：EP16756542.3
申请日：2016-02-29
申请人： The Johns Hopkins University
发明人： BRODSKY, Robert
IPC分类号： G01N33/50 , C12Q1/02 , A61K39/395 , A61P37/00
CPC分类号： G01N33/5091 , A61P7/00 , C07K16/18 , C07K2317/24 , C07K2317/76 , G01N2440/00 , G01N2800/22
摘要： The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating atypical hemolytic uremic syndrome, antiphospholipid antibody syndrome and other disorders of the alternative pathway of complement activation. In one embodiment, a method comprises the steps of (a) incubating or contacting serum obtained from a patient suspected of having atypical hemolytic uremic syndrome (aHUS) with a glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient cell line; and (b) performing a cell viability assay on the cells from step (a). In a specific embodiment, the method further comprises the step of diagnosing the patient as having aHUS based on a statistically significant increased difference of non-viable cells from the patient serum as compared to a control.

82. 发明公开

EP3259594A1 BIOMARKERS OF MYOCARDIAL INJURY 审中-公开
标题翻译：心肌损伤的生物标志物
公开(公告)号：EP3259594A1
公开(公告)日：2017-12-27
申请号：EP16753221.7
申请日：2016-02-22
申请人： The Johns Hopkins University
发明人： VAN EYK, Jennifer , FU, Qin
IPC分类号： G01N33/53 , G01N27/64 , G01N33/68
CPC分类号： G01N33/6893 , G01N33/6848 , G01N2440/00 , G01N2800/324
摘要： The present invention relates to the field of myocardial injury. More specifically, the present invention provides methods and compositions useful in the diagnosis, prognosis and/or assessment of myocardial injury. In a specific embodiment, a method comprises the steps of (a) diagnosing a subject as having myocardial injury based on the statistically significant over expression of one or more markers described herein compared to a baseline value, wherein the markers are measured in a biological sample obtained from the subject; and (b) treating the subject with one or more of an anti-thrombolysis agent, coronary bypass surgery or angioplasty.

83. 发明公开

EP3042201A4 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS 有权
标题翻译： ZUSAMMENSETZUNGEN UND VERFAHREN ZUR DIAGNOSE RHEUMATOIDER ARTHRITIS
公开(公告)号：EP3042201A4
公开(公告)日：2017-03-29
申请号：EP15825438
申请日：2015-07-22
申请人： INOVA DIAGNOSTICS INC , LEIDEN UNIV MEDICAL CENTER
发明人： MAHLER MICHAEL , TROUW LEENDERT A , DRIJFHOUT JAN WOUTER , VAN VEELEN PETER , TOES RENÉ , HUIZINGA TOM
IPC分类号： G01N33/564 , C07K14/81
CPC分类号： G01N33/564 , C07K1/1075 , C07K14/8125 , G01N2333/8125 , G01N2440/00 , G01N2800/102
摘要： The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.
摘要翻译：本公开涉及分子生物学领域，更具体地涉及用于在类风湿性关节炎（RA）患者的血清中检测抗氨基甲酰化蛋白（抗CarP）抗体的方法。

84. 发明公开

EP3132269A2 DIAGNOSIS OF CHRONIC KIDNEY DISEASE BY QUANTITATIVE ANALYSIS OF POST-TRANSLATIONAL MODIFICATIONS OF PLASMA PROTEINS 有权
标题翻译： DIAGNOSE VON CHRONISCHER NIERENERKRANKUNG DURCH定量分析仪VON POSTTRANSLATIONALEN MODIFIKATIONEN VON PLASMAPROTEINEN
公开(公告)号：EP3132269A2
公开(公告)日：2017-02-22
申请号：EP15714830.5
申请日：2015-04-09
申请人： eXcorLab GmbH
发明人： LEMKE, Horst-Dieter , RÜTH, Marieke , JANKOWSKI, Joachim , JANKOWSKI, Vera
IPC分类号： G01N33/68 , C07K16/18
CPC分类号： G01N33/6893 , C07K16/18 , C07K2317/30 , C07K2317/92 , G01N2333/765 , G01N2440/00 , G01N2800/347
摘要： The present invention relates to methods for diagnosing and/or monitoring the onset or progression of chronic kidney disease (CKD) in a patient by the analysis of post-translational modification of plasma proteins. The present invention provides improved means for diagnosing chronic kidney disease (CKD) especially for the early recognition of CKD.
摘要翻译：本发明涉及通过分析血浆蛋白的翻译后修饰来诊断和/或监测患者中慢性肾脏疾病（CKD）发病或进展的方法。本发明提供用于诊断慢性肾脏疾病（CKD）的改进方法，特别是用于CKD的早期识别。

85. 发明公开

EP3094639A1 METHOD FOR OPTIMIZING POST-TRANSLATIONAL MODIFICATIONS ON RECOMBINANT PROTEINS 审中-公开
标题翻译：方法以优化重组蛋白翻译后修饰
公开(公告)号：EP3094639A1
公开(公告)日：2016-11-23
申请号：EP15734830.1
申请日：2015-01-13
申请人： Leszcyniecka, Magdalena , Shulga-Morskoy, Sergey
发明人： Leszcyniecka, Magdalena , Shulga-Morskoy, Sergey
IPC分类号： C07K1/00 , C12N5/02 , C12P21/00
CPC分类号： C12P21/02 , C07K16/32 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C12N2510/02 , G01N2440/00
摘要： A method for optimizing post-translational modifications of recombinant proteins expressed in living cells is described. More particularly, a method for modulation of host proteins in living cells that control PTMs on recombinant proteins is described that has particularly useful applications in developing manufacturing process changes or in biosimilar development. The goal of this modulation is to produce a recipe for production of a recombinant protein in the new process or in the biosimilar that will produce a targeted PTM profile in the resulting protein product. In the method one or more modulators are selected, as from a modulator library, which affect the activity of host proteins. These modulators are added to media during production such that the resulting product matches the PTMs of the reference product. The ideal set of modulators and their concentrations are identified through a unique iterative process and the combined modulators and their concentrations constitute a recipe for growth media for the production of said recombinant protein. The methodology to obtain such a recipe described herein may then be used in many applications, such as optimizing new batches of recombinant protein drugs, developing biosimilar or bio-better drugs.

86. 发明公开

EP2562539A4 METHOD OF ANALYZING HEMOGLOBINS 有权转让
标题翻译：法分析血红蛋白
公开(公告)号：EP2562539A4
公开(公告)日：2015-01-28
申请号：EP11765385
申请日：2011-03-22
申请人： SEKISUI MEDICAL CO LTD
发明人： TAIRA HIROAKI , OKA TAKAYUKI
IPC分类号： G01N30/88 , G01N30/06 , G01N30/34 , G01N30/96 , G01N33/72
CPC分类号： G01N33/721 , B01D15/362 , G01N30/06 , G01N30/34 , G01N30/96 , G01N2030/067 , G01N2030/8822 , G01N2030/8831 , G01N2440/00

87. 发明公开

EP2773964A1 METHOD FOR DETERMINATION OF PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS 审中-公开
标题翻译：方法用于确定的药理学性质的重组蛋白
公开(公告)号：EP2773964A1
公开(公告)日：2014-09-10
申请号：EP12844950.1
申请日：2012-11-02
申请人： STC Biologics, Inc.
发明人： LESZCZYNIECKA, Magdalena
IPC分类号： G01N33/68 , G01N33/53 , A61K38/00
CPC分类号： G01N33/557 , G01N33/68 , G01N2440/00 , G01N2500/04
摘要： The present invention is directed to a method for obtaining an in vitro pharmacological model of a recombinant protein drug in a given host. A plurality of biomolecules are selected which are known or suspected to influence pharmacology of the recombinant protein in the host via a binding interaction with the recombinant protein. The recombinant protein is contacted with each selected biomolecule and the binding kinetics parameters for each interaction are determined using a binding assay. These steps are then repeated with all selected biomolecules to produce a plurality of binding kinetics parameters for the selected biomolecules. The combined results provide an in vitro pharmacological model of the recombinant protein in the host. The in vitro pharmacological model may then be used in several applications, such as optimizing new batches of recombinant protein drugs, developing biosimilar or bio- better drug candidates.

88. 发明公开

EP2673293A2 SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF 有权
标题翻译：修饰蛋白SURROGATE及其用途翻译后
公开(公告)号：EP2673293A2
公开(公告)日：2013-12-18
申请号：EP12744613.6
申请日：2012-02-10
申请人： President and Fellows of Harvard College
发明人： CHOREV, Michael , HALPERIN, Jose, A.
IPC分类号： C07K14/435 , C07K16/18 , G01N33/533 , G01N33/574
CPC分类号： G01N33/6893 , C07K14/70596 , C07K16/2896 , C07K16/44 , G01N33/564 , G01N33/6872 , G01N2333/70596 , G01N2440/00 , G01N2440/38 , G01N2800/042
摘要： The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens. The surrogate compounds may be prepared by covalently joining two or more polypeptide epitopes using one or more linkers, wherein at least one of the epitopes comprises a post-translational modification. In one aspect, the surrogate compounds of the invention comprise a C-terminal epitope and a glycated epitope of human CD59. The inventive methods allow quantification of the levels of glycated CD59 in the serum in human subjects, particularly those with diabetes or pre-diabetes. This technological platform of post-translationally modified protein surrogates can be applied to other diseases associated with post-translationally modified proteins (e.g., autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus). In another aspect, the invention provides antibodies that bind specifically to the compounds of the invention and methods for producing such antibodies.

89. 发明公开

EP2341345A1 Pharmacological profiling of drugs with cell-based assays 审中-公开
标题翻译： Pharmakologische Profilierung von Arzneimitteln mit zellenbasierten Assays
公开(公告)号：EP2341345A1
公开(公告)日：2011-07-06
申请号：EP10015839.3
申请日：2005-08-18
申请人： Odyssey Thera, Inc.
发明人： Westwick, John , Yu, Helen , MacDonald, Marnie L.
IPC分类号： G01N33/50 , C12Q1/02
CPC分类号： C12Q1/025 , G01N33/5023 , G01N33/5035 , G01N33/5041 , G01N33/5097 , G01N2440/00 , G01N2440/10 , G01N2440/12 , G01N2440/36 , G01N2440/38 , G01N2500/10
摘要： The instant invention provides a method for establishing safety profiles for chemical compounds, as well as pharmacological profiling said method comprising (A) testing the effects of said chemical compounds on the amount and/or post-translational modifications of two or more macromolecules in intact cells; (B) constructing a pharmacological profile based on the results of said tests; and (C) comparing said profile to the profile(s) of drugs with established safety characteristics. Additionally, the invention is also directed to a composition comprising an assay panel, said panel comprising at least one high-content assay for the amount and/or post-translational modification of a protein and at least one high-content assay for the amount and/or subcellular location of a protein-protein interaction.
摘要翻译：本发明提供了一种用于建立化学化合物的安全性的方法以及药理学分析，所述方法包括（A）测试所述化合物对完整细胞中两种或更多种大分子的量和/或翻译后修饰的影响 ; （B）基于所述测试的结果构建药理学特征; 和（C）将所述概况与具有确定的安全特征的药物的概况进行比较。此外，本发明还涉及包含测定面板的组合物，所述面板包含至少一种用于蛋白质的量和/或翻译后修饰的高含量测定，以及至少一种高含量测定法，其量为和 /或蛋白质 - 蛋白质相互作用的亚细胞位置。

90. 发明授权

EP2861788B1 METHODS OF DETECTING DISEASES OR CONDITIONS USING CIRCULATING DISEASED CELLS 有权
公开(公告)号：EP2861788B1
公开(公告)日：2018-10-10
申请号：EP13803970.6
申请日：2013-06-14
申请人： Progenity, Inc.
发明人： STYLLI, Harry
IPC分类号： C40B40/04 , G01N33/574 , G01N33/569 , G01N33/68 , C12Q1/68
CPC分类号： G01N33/57492 , C12Q1/6809 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/56966 , G01N33/57484 , G01N33/6848 , G01N2440/00
摘要： This invention provides methods of using circulating diseased cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using circulating diseased cells to identify markers of diseases or conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式